|
|
|
|
|
|
|
|
open access
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
.... It should be noted that because there were no responses in patients
with platinum-refractory or clear cell disease, logistic regression results for these parameters were nonestimable....Although the regression models
suggest that platinum-refractory status is a stronger predictor
of poor outcomes than clear cell histology, examination of a
larger data set is needed to increase confidence in this conclusion.....
Objective: Primary platinum-resistant epithelial
ovarian cancer (EOC) is an area of unmet medical need. There is limited
evidence from small studies that platinum-based combinations can
overcome “resistance” in a proportion of patients. We investigated the
efficacy and toxicity of platinum-based combination chemotherapy in the
platinum-resistant and platinum-refractory setting.
Methods:
Epirubicin, cisplatin, and capecitabine (ECX) combination chemotherapy
was used at our institution for the treatment of relapsed EOC. From the
institutional database, we identified all patients with primary
platinum-refractory or platinum-resistant relapse treated with ECX as
second-line therapy between 2001 and 2012. We extracted demographic,
clinical, treatment, and toxicity data and outcomes. We used logistic
and Cox regression models to identify predictors of response and
survival respectively.
Results:
Thirty-four 34 patients (8 refractory, 26 resistant) were treated with
ECX. Response Evaluation Criteria In Solid Tumors (RECIST) response rate
was 45%, median progression-free survival (PFS) was 6.4 months, and
overall survival (OS) was 10.6 months. Platinum-resistant patients had
better outcomes than did platinum-refractory patients (response rate,
54% vs 0%, P = 0.047; PFS 7.2 vs 1.8 months, P < 0.0001; OS 14.4 vs 3 months, P
< 0.001). In regression models, time to progression after first-line
treatment and platinum-refractory status were the strongest predictors
of response and PFS or OS, respectively. Patients with time to
progression after first-line treatment longer than 3 months showed PFS
and OS of 7.9 and 14.7 months, respectively. Toxicity was manageable,
with only 13% of cycles administered at reduced doses.
Conclusions:
Epirubicin, cisplatin, and capecitabine seems to be active in
platinum-resistant relapsed EOC with manageable toxicity. Further
prospective investigation of platinum-anthracycline combinations is
warranted in patients who relapse 3 to 6 months after first-line
platinum-taxane treatment.
Full text article:
Epithelial ovarian cancer (EOC) is a significant cause of morbidity and the commonest cause of death from gynecologic cancer.1
For most patients presenting with stage III-IV disease, first-line
treatment consists of debulking surgery and chemotherapy with a platinum
taxane doublet, most commonly carboplatin and paclitaxel.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.